Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Karlsruhe – page 64

883 clinical trials in Karlsruhe, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Karlsruhe at a glance
883
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

883 trials in Karlsruhe

Open in trial search

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Plasma cell myeloma

Not recruiting

Study on Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed, Refractory, or Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Short-bowel syndrome

Not recruiting

Long-term safety study of apraglutide (weekly injections) in patients with Short Bowel Syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apraglutide
  • Sponsor:VectivBio AG

C3 glomerulopathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Complement 3 Glomerulopathy

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Deafness neurosensory

Not recruiting

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AC102
  • Sponsor:AudioCure Pharma GmbH

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Plasma cell myeloma

Not recruiting

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a 36-Week Refill System

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Glioma

Not recruiting

Study of Vorasidenib for Patients with Residual or Recurrent Grade 2 Glioma with IDH1 or IDH2 Mutation

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Vorasidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Karlsruhe

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on colorectal cancer, breast cancer, and various types of lymphomas. Studies evaluate novel combination therapies and targeted treatments for patients with different stages of disease.

  • Metastatic colorectal cancer treatments
  • Triple-negative breast cancer therapy
  • B-cell lymphoma interventions

Advanced trials exploring immunotherapy combinations and precision medicine approaches.

02 Hematologic Malignancies

Groundbreaking studies in acute myeloid leukemia and chronic lymphocytic leukemia, testing innovative drug combinations and targeted therapies.

  • Novel AML treatment combinations
  • CLL/SLL therapeutic approaches
  • Multiple myeloma interventions

Focus on improving survival rates through personalized treatment strategies.

03 Chronic Conditions

Research addressing chronic kidney disease, pulmonary diseases, and metabolic disorders. Studies evaluate new therapeutic options for managing long-term health conditions.

  • COPD treatment innovations
  • Kidney disease management
  • Sleep apnea interventions

Emphasis on improving quality of life and disease outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.